The emerging anti-proliferative role of Nutlin-3 in the pathogenesis of systemic malignancies

Cancer Biology and Therapy

Volumn 14, Issue 1, 2013, Pages 5-

  Kapoor, Shailendra ^a  

^a NONE

Author keywords

Cancer; Nutlin 3; Tumor

Indexed keywords

CISPLATIN; DOXORUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; MONOCYTE CHEMOTACTIC PROTEIN 1; NUTLIN 3; PROTEIN MDM2; PROTEIN P53; PROTEIN P73; RESVERATROL;

ADD ON THERAPY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; COLORECTAL CARCINOMA; HUMAN; LETTER; OVARY CARCINOMA; PROSTATE CARCINOMA; STOMACH CARCINOMA;

EID: 84872123627     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.22629     Document Type: Letter

References (10)

1. Zhang Y, Zhang Q, Zeng SX, Zhang Y, Mayo LD, Lu H. Inauhzin and Nutlin3 synergistically activate p53 and suppress tumor growth. Cancer Biol Ther 2012; 13:915-24; PMID:22785205; http://dx.doi.org/10.4161/cbt.20844.
2. Endo S, Yamato K, Hirai S, Moriwaki T, Fukuda K, Suzuki H, et al. Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells. Cancer Sci 2011; 102:605-13; PMID:21205074; http://dx.doi.org/10. 1111/j.1349-7006.2010.01821.x.
3. Nadler-Milbauer M, Apter L, Haupt Y, Haupt S, Barenholz Y, Minko T, et al. Synchronized release of Doxil and Nutlin-3 by remote degradation of polysaccharide matrices and its possible use in the local treatment of colorectal cancer. J Drug Target 2011; 19:859-73; PMID:22082104; http://dx.doi.org/10.3109/1061186X.2011.622401.
4. Zheng T, Wang J, Song X, Meng X, Pan S, Jiang H, et al. Nutlin-3 cooperates with doxorubicin to induce apoptosis of human hepatocellular carcinoma cells through p53 or p73 signaling pathways. J Cancer Res Clin Oncol 2010; 136:1597-604; PMID:20174822; http://dx.doi.org/10.1007/s00432-010-0817-8.
5. Dey A, Wong ET, Bist P, Tergaonkar V, Lane DP. Nutlin-3 inhibits the NFkappaB pathway in a p53-dependent manner: implications in lung cancer therapy. Cell Cycle 2007; 6:2178-85; PMID:17786042; http://dx.doi.org/10.4161/cc.6.17. 4643.
6. Marimuthu P, Kaur K, Kandalam U, Jasani V, Bukhari N, Nguyen M, et al. Treatment of ovarian cancer cells with nutlin-3 and resveratrol combination leads to apoptosis via caspase activation. J Med Food 2011; 14:46-52; PMID:21186985; http://dx.doi.org/10.1089/jmf.2009.0270.
7. Logan IR, McNeill HV, Cook S, Lu X, Lunec J, Robson CN. Analysis of the MDM2 antagonist nutlin-3 in human prostate cancer cells. Prostate 2007; 67:900-6; PMID:17440969; http://dx.doi.org/10.1002/pros.20568.
8. Supiot S, Hill RP, Bristow RG. Nutlin-3 radiosensitizes hypoxic prostate cancer cells independent of p53. Mol Cancer Ther 2008; 7:993-9; PMID:18413812; http://dx.doi.org/10.1158/1535-7163.MCT-07-0442.
9. Ye F, Lattif AA, Xie J, Weinberg A, Gao S. Nutlin-3 induces apoptosis, disrupts viral latency and inhibits expression of angiopoietin-2 in Kaposi sarcoma tumor cells. Cell Cycle 2012; 11:1393-9; PMID:22421142; http://dx.doi.org/10.4161/cc.19756.
10. Michaelis M, Rothweiler F, Barth S, Cinatl J, van Rikxoort M, Löschmann N, et al. Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells. Cell Death Dis 2011;2:e243; PMID:22170099; http://dx.doi.org/10.1038/cddis.2011.129.